KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or “The Company”), today announced that an abstract titled Intralesional rose bengal for treatment of melanoma has been accepted for a poster presentation at the annual meeting of the American Society of Clinical Oncology being held in Chicago June 3-7, 2016.
